Inherited microcytic anemias.


Journal

Hematology. American Society of Hematology. Education Program
ISSN: 1520-4383
Titre abrégé: Hematology Am Soc Hematol Educ Program
Pays: United States
ID NLM: 100890099

Informations de publication

Date de publication:
04 12 2020
Historique:
entrez: 4 12 2020
pubmed: 5 12 2020
medline: 5 5 2021
Statut: ppublish

Résumé

Inherited microcytic anemias can be broadly classified into 3 subgroups: (1) defects in globin chains (hemoglobinopathies or thalassemias), (2) defects in heme synthesis, and (3) defects in iron availability or iron acquisition by the erythroid precursors. These conditions are characterized by a decreased availability of hemoglobin (Hb) components (globins, iron, and heme) that in turn causes a reduced Hb content in red cell precursors with subsequent delayed erythroid differentiation. Iron metabolism alterations remain central to the diagnosis of microcytic anemia, and, in general, the iron status has to be evaluated in cases of microcytosis. Besides the very common microcytic anemia due to acquired iron deficiency, a range of hereditary abnormalities that result in actual or functional iron deficiency are now being recognized. Atransferrinemia, DMT1 deficiency, ferroportin disease, and iron-refractory iron deficiency anemia are hereditary disorders due to iron metabolism abnormalities, some of which are associated with iron overload. Because causes of microcytosis other than iron deficiency should be considered, it is important to evaluate several other red blood cell and iron parameters in patients with a reduced mean corpuscular volume (MCV), including mean corpuscular hemoglobin, red blood cell distribution width, reticulocyte hemoglobin content, serum iron and serum ferritin levels, total iron-binding capacity, transferrin saturation, hemoglobin electrophoresis, and sometimes reticulocyte count. From the epidemiological perspective, hemoglobinopathies/thalassemias are the most common forms of hereditary microcytic anemia, ranging from inconsequential changes in MCV to severe anemia syndromes.

Identifiants

pubmed: 33275715
pii: 474326
doi: 10.1182/hematology.2020000158
pmc: PMC7727536
doi:

Substances chimiques

Iron E1UOL152H7

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

465-470

Informations de copyright

© 2020 by The American Society of Hematology.

Déclaration de conflit d'intérêts

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Références

Blood. 2015 Oct 22;126(17):1981-9
pubmed: 26289639
Eur J Intern Med. 2017 Jul;42:16-23
pubmed: 28528999
Blood. 2014 Jan 16;123(3):326-33
pubmed: 24215034
Semin Hematol. 2015 Oct;52(4):270-8
pubmed: 26404439
N Engl J Med. 2019 Sep 5;381(10):933-944
pubmed: 31483964
Haematologica. 2020 Jan 31;105(2):260-272
pubmed: 31949017
Transl Gastroenterol Hepatol. 2020 Apr 05;5:25
pubmed: 32258529
Br J Haematol. 2013 Jan;160(1):12-24
pubmed: 23057559
Br J Haematol. 2016 Feb;172(4):512-23
pubmed: 26491866
Haematologica. 2009 Mar;94(3):395-408
pubmed: 19181781
Blood. 2018 Apr 19;131(16):1790-1794
pubmed: 29523504
Blood. 2019 Jan 3;133(1):51-58
pubmed: 30401707
Hum Mutat. 2010 May;31(5):E1390-405
pubmed: 20232450
Am J Hematol. 2018 May;93(5):672-682
pubmed: 29396846
Am Fam Physician. 2010 Nov 1;82(9):1117-22
pubmed: 21121557
Indian J Hum Genet. 2014 Apr;20(2):101-19
pubmed: 25400338
Front Physiol. 2017 Dec 19;8:1076
pubmed: 29311991
Haematologica. 2016 May;101(5):e173-6
pubmed: 26944476
Front Physiol. 2019 Oct 09;10:1294
pubmed: 31649559
Blood. 2019 Nov 14;134(20):1697-1707
pubmed: 31554636
Crit Rev Clin Lab Sci. 2015;52(5):256-72
pubmed: 26292073
N Engl J Med. 2020 Mar 26;382(13):1219-1231
pubmed: 32212518
Haematologica. 2020 Jul;105(7):1835-1844
pubmed: 31582543
Am J Hematol. 2019 Nov;94(11):1227-1235
pubmed: 31400017
Blood. 2018 Oct 4;132(14):1473-1477
pubmed: 30097509
Cochrane Database Syst Rev. 2020 Feb 28;2:CD008959
pubmed: 32107773
N Engl J Med. 2019 Sep 19;381(12):1148-1157
pubmed: 31532961

Auteurs

Maria Domenica Cappellini (MD)

Dipartimento di Scienze Cliniche e di Comunità, Università degli Studi di Milano, Milan, Italy.

Roberta Russo (R)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy; and.
CEINGE Biotecnologie Avanzate, Naples, Italy.

Immacolata Andolfo (I)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy; and.
CEINGE Biotecnologie Avanzate, Naples, Italy.

Achille Iolascon (A)

Dipartimento di Medicina Molecolare e Biotecnologie Mediche, Università degli Studi di Napoli Federico II, Naples, Italy; and.
CEINGE Biotecnologie Avanzate, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH